NewLink Genetics Corporation (NASDAQ:NLNK) – Investment analysts at Cantor Fitzgerald issued their FY2016 earnings per share estimates for NewLink Genetics Corporation in a report released on Tuesday. Cantor Fitzgerald analyst M. Goldstein anticipates that the brokerage will earn ($2.91) per share for the year. Cantor Fitzgerald also issued estimates for NewLink Genetics Corporation’s FY2017 earnings at ($1.27) EPS.

A number of other analysts have also issued reports on the stock. Zacks Investment Research raised shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Saturday. Jefferies Group reissued a “hold” rating and set a $12.00 target price on shares of NewLink Genetics Corporation in a research note on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. NewLink Genetics Corporation has an average rating of “Buy” and a consensus target price of $23.57.

Earnings History and Estimates for NewLink Genetics Corporation (NASDAQ:NLNK)

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Comments on NewLink Genetics Corporation’s FY2016 Earnings (NLNK)” was originally reported by Watch List News and is the propert of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at http://www.watchlistnews.com/cantor-fitzgerald-comments-on-newlink-genetics-corporations-fy2016-earnings-nlnk/1061077.html.

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) opened at 12.02 on Friday. The company’s market capitalization is $350.19 million. The firm’s 50-day moving average is $11.18 and its 200-day moving average is $11.69. NewLink Genetics Corporation has a 1-year low of $9.23 and a 1-year high of $29.12.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings data on Tuesday, November 1st. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.06. The business earned $15.35 million during the quarter, compared to analyst estimates of $3.83 million. NewLink Genetics Corporation had a negative net margin of 303.49% and a negative return on equity of 56.48%.

Institutional investors have recently made changes to their positions in the company. American International Group Inc. increased its position in shares of NewLink Genetics Corporation by 1.4% in the second quarter. American International Group Inc. now owns 12,455 shares of the company’s stock worth $140,000 after buying an additional 174 shares in the last quarter. ProShare Advisors LLC increased its position in shares of NewLink Genetics Corporation by 1.0% in the second quarter. ProShare Advisors LLC now owns 24,157 shares of the company’s stock worth $272,000 after buying an additional 250 shares in the last quarter. California State Teachers Retirement System increased its position in shares of NewLink Genetics Corporation by 0.7% in the third quarter. California State Teachers Retirement System now owns 45,668 shares of the company’s stock worth $686,000 after buying an additional 300 shares in the last quarter. Zacks Investment Management increased its position in shares of NewLink Genetics Corporation by 2.1% in the second quarter. Zacks Investment Management now owns 24,166 shares of the company’s stock worth $272,000 after buying an additional 506 shares in the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of NewLink Genetics Corporation by 5.8% in the second quarter. Nationwide Fund Advisors now owns 14,160 shares of the company’s stock worth $159,000 after buying an additional 770 shares in the last quarter. Institutional investors and hedge funds own 46.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Comments on NewLink Genetics Corporation’s FY2016 Earnings (NLNK)” was originally reported by Watch List News and is the propert of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at http://www.watchlistnews.com/cantor-fitzgerald-comments-on-newlink-genetics-corporations-fy2016-earnings-nlnk/1061077.html.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

5 Day Chart for NASDAQ:NLNK

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.